WVE vs. AXSM, BPMC, TLX, ELAN, LNTH, NUVL, CYTK, VRNA, GRFS, and TGTX
Should you be buying Wave Life Sciences stock or one of its competitors? The main competitors of Wave Life Sciences include Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Elanco Animal Health (ELAN), Lantheus (LNTH), Nuvalent (NUVL), Cytokinetics (CYTK), Verona Pharma (VRNA), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.
Wave Life Sciences vs.
Axsome Therapeutics (NASDAQ:AXSM) and Wave Life Sciences (NASDAQ:WVE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations.
Axsome Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -1.09, meaning that its stock price is 209% less volatile than the S&P 500.
Wave Life Sciences has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Wave Life Sciences, indicating that it is currently the more affordable of the two stocks.
Wave Life Sciences has a net margin of -66.50% compared to Axsome Therapeutics' net margin of -74.47%. Axsome Therapeutics' return on equity of -223.51% beat Wave Life Sciences' return on equity.
Axsome Therapeutics presently has a consensus target price of $157.64, indicating a potential upside of 15.25%. Wave Life Sciences has a consensus target price of $22.22, indicating a potential upside of 97.71%. Given Wave Life Sciences' higher possible upside, analysts plainly believe Wave Life Sciences is more favorable than Axsome Therapeutics.
Axsome Therapeutics received 107 more outperform votes than Wave Life Sciences when rated by MarketBeat users. Likewise, 70.25% of users gave Axsome Therapeutics an outperform vote while only 67.85% of users gave Wave Life Sciences an outperform vote.
In the previous week, Axsome Therapeutics had 53 more articles in the media than Wave Life Sciences. MarketBeat recorded 55 mentions for Axsome Therapeutics and 2 mentions for Wave Life Sciences. Wave Life Sciences' average media sentiment score of 1.17 beat Axsome Therapeutics' score of 0.46 indicating that Wave Life Sciences is being referred to more favorably in the news media.
81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are owned by institutional investors. 22.4% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 29.1% of Wave Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Axsome Therapeutics and Wave Life Sciences tied by winning 9 of the 18 factors compared between the two stocks.
Get Wave Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Wave Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:WVE) was last updated on 2/21/2025 by MarketBeat.com Staff
